Issued claims include therapeutic protein, gene therapy and cell therapy applicationsPatent extends MANF Therapeutics' exclusivity for MANF treatment of Parkinson's disease in Japan into 2029SAN FRANCISCO, Dec. 20, 2017 — via OTC PR Wire — Amarantus Bioscience Holdings, Inc. (OTCPK:AMBS), a US-based biotechnology holding company with wholly-owned subsidiaries developing first-in-class orphan neurologic, regenerative medicine and ophthalmic therapies, today announced that its wholly-owned subsidiary MANF Therapeutics, Inc. was issued a patent by the Japan Patent Office entitled “Neurodegenerative Disorders” covering the use of MANF as a treatment for Parkinson's disease. The issued patent extends coverage for MANF Therapeutics' use of MANF in the treatment of Parkinson's in Japan into 2031.The key claim issued in this patent is “Use of MANF for the manufacture of a medicament for administration to the substantia nigra region of the brain for treating Parkinson's disease.” The substantia nigra is a key area of the brain where dopamine producing neurons degenerate in Parkinson's disease. Additional claims covering combinations with MANF and other therapeutic moieties were also granted, as well as gene therapy and cell therapy claims. This patent adds to Amarantus' extensive international intellectual property portfolio covering compositions of matter, methods of use and formulations for MANF in numerous disease indications.Significant pre-clinical efficacy and delivery data supporting the use of MANF in the treatment of Parkinson's disease is available in peer-reviewed scientific journals, as well as summary results that Amarantus previously made publicly available. Certain data is available at the links below:Mesencephalic Astrocyte-Derived Neurotrophic Factor Is Neurorestorative in Rat Model of Parkinson's DiseaseConvection-enhanced delivery of MANF Volume of distribution analysis in porcine putamen and substantia nigraComparison and Actions of MANF and GDNF in Rodent Models of Parkinson's DiseaseA Whitepaper on MANF commissioned by Amarantus in Q2/2013 is available here: http://content.stockpr.com/amarantus/files/pdf/MANF+WhitePaper+2013-04-30+FINAL.pdfAbout Amarantus Bioscience Holdings, Inc.Amarantus Bioscience Holdings (AMBS) is a biotechnology company developing treatments and diagnostics for diseases in the areas of neurology, regenerative medicine and orphan diseases through its subsidiaries. AMBS' wholly-owned subsidiary Elto Pharma, Inc. has development rights to eltoprazine, a Phase 2b-ready small molecule indicated for Parkinson's disease levodopa-induced dyskinesia, Alzheimer's aggression and adult ADHD. AMBS acquired the rights to the Engineered Skin Substitute program (ESS), a regenerative medicine-based approach for treating severe burns with full-thickness autologous skin grown in tissue culture that is being pursued by AMBS' wholly-owned subsidiary Cutanogen Corporation. AMBS' wholly-owned subsidiary MANF Therapeutics, Inc. owns key intellectual property rights and licenses from a number of prominent universities related to the development of the therapeutic protein known as mesencephalic astrocyte-derived neurotrophic factor (MANF). MANF Therapeutics, Inc. is developing MANF-based products as treatments for brain and ophthalmic disorders. MANF was discovered by the Company's Chief Scientific Officer John Commissiong, PhD. Dr. Commissiong discovered MANF from AMBS' proprietary discovery engine PhenoGuard. AMBS also owns approximately 80 million shares of Avant Diagnostics, Inc. via the sale of its wholly-owned subsidiary Amarantus Diagnostics, Inc. that occurred in May 2016.For further information please visit www.Amarantus.com, or connect with the Amarantus on Facebook, LinkedIn, Twitter and Google+.About MANF Therapeutics, Inc.MANF (mesencephalic-astrocyte-derived neurotrophic factor) is believed to have broad potential because it is a naturally-occurring protein produced by the body to reduce/prevent apoptosis (cell death) in response to injury or disease, via the unfolded protein response. By administering exogenously produced MANF the body, Amarantus is seeking to use a regenerative medicine approach to assist the body with higher quantities of MANF when needed. Amarantus is the front-runner and primary holder of intellectual property around MANF, and is initially focusing on the development of MANF-based protein therapeutics.MANF's lead indication is retinitis pigmentosa, and additional indications including Parkinson's disease, diabetes and Wolfram's syndrome are envisioned. Further applications for MANF may include Alzheimer's disease, traumatic brain injury, myocardial infarction, antibiotic-induced ototoxicity and certain other orphan diseases.In April 2017, Amarantus incorporated the wholly-owned subsidiary MANF Therapeutics, Inc. to focus on progressing preclinical and clinical development of MANF.Forward-Looking StatementsCertain statements, other than purely historical information, including estimates, projections, statements relating to our business plans, objectives, and expected operating results, and the assumptions upon which those statements are based, are forward-looking statements. These forward-looking statements generally are identified by the words “believes,” “project,” “expects,” “anticipates,” “estimates,” “intends,” “strategy,” “plan,” “may,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. Forward-looking statements are based on current expectations and assumptions that are subject to risks and uncertainties which may cause actual results to differ materially from the forward-looking statements. Our ability to predict results or the actual effect of future plans or strategies is inherently uncertain. Factors which could have a material adverse effect on our operations and future prospects on a consolidated basis include, but are not limited to: changes in economic conditions, legislative/regulatory changes, availability of capital, interest rates, competition, and generally accepted accounting principles. These risks and uncertainties should also be considered in evaluating forward-looking statements and undue reliance should not be placed on such statements.Amarantus Investor and Media Contact:Ascendant Partners, LLCRichard Galterio+1-732-410-9810[email protected]Source: Amarantus Bioscience Holdings, Inc.
Latest posts by Sarah Thompson (see all)
- Fainsbert Mase Brown & Sussman, LLP Completes Acquisition Closing on 3.1 Million Sq. Ft. IBM Campus in Minnesota - February 24, 2018
- Marketa McGuire Named Bureau of Reclamation's 2018 Engineer of the Year - February 24, 2018
- Oncolytics Biotech(R) Announces Results from Special Meeting of Shareholders - February 23, 2018